Drug Type Small molecule drug |
Synonyms 亚胺培南西司他丁钠福诺巴坦 |
Action inhibitors |
Mechanism DPEP1 inhibitors(dipeptidase 1 inhibitors), PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), β-lactamase inhibitors(Beta Lactamase inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC28H43N5NaO9S2 |
InChIKeyXWIKEETXNRMEDP-KJWPAVRRSA-N |
CAS Registry85960-17-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Complicated urinary tract infection | Phase 1 | China | 14 Nov 2024 | |
Hospital-acquired pneumonia | Phase 1 | China | 14 Nov 2024 | |
Pneumonia, Ventilator-Associated | Phase 1 | China | 14 Nov 2024 | |
Hospital acquired bacterial pneumonia | IND Approval | China | 22 Sep 2024 | |
Ventilator associated bacterial pneumonia | IND Approval | China | 22 Sep 2024 |